Phase 3 Readout

ABVX: Phase 3 Topline: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safet

Name: Phase 3 Topline: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safet
Start: 2030-05-01
End: 2030-05-01

May 1, 2030. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: May 1, 2030
Company: Abivax SA (ABVX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safet

May 1, 2030

ABVX overview →

Company: Abivax SA (ABVX)
Indication: Ulcerative Colitis